Staurosporine alleviates cisplatin chemoresistance in human cancer cell models by suppressing the induction of SQSTM1/p62

KHALDOON ALSAMMAN1 and OMAR S. EL-MASRY1,2

1Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, Imam Abdulrahman Bin Faisal University, Dammam 31441, Kingdom of Saudi Arabia; 2Department of Applied Medical Chemistry, Medical Research Institute, University of Alexandria, Alexandria 21561, Egypt

Received March 22, 2018; Accepted July 17, 2018

DOI: 10.3892/or.2018.6615

Abstract. Cancer is one of the leading causes of mortality worldwide. Platinum-based chemotherapeutic agents such as cisplatin are the first line of treatment for many types of cancers. However, the development of cisplatin resistance after prolonged treatment is a common cause of cancer recurrence. In the present study, we investigated an approach designed to overcome resistance to cisplatin involving co-treatment with a second chemotherapeutic agent, staurosporine, and examined the role of sequestosome 1 (SQSTM1/p62) in enhancing cellular sensitivity to cisplatin. We utilized experimental models of three different cancers comprising cell lines derived from colon, breast, and ovarian tumors and investigated cell proliferation, morphology and p62 levels after treatment with cisplatin, staurosporine, or a combination of the two. Western blot analysis showed that cisplatin treatment resulted in elevation of p62 levels when compared to the corresponding control cells. Conversely, treatment with staurosporine resulted in a marked reduction in p62 levels when compared to the corresponding control cells. Conversely, treatment with staurosporine resulted in a marked reduction in p62 levels in all three cell types and abrogated the cisplatin-induced upregulation of p62. These results suggest that staurosporine could sensitize cancer cells to cisplatin via a mechanism involving downregulation of p62.

Introduction

Ovarian, breast and colorectal cancers are highly prevalent worldwide, representing a leading cause of human mortality.

Breast cancer is the most commonly diagnosed cancer in women (1), whereas ovarian cancer ranks third among reproductive cancers in women and accounts for ~4% of all malignancies (2). Colorectal cancer was recently reported as the third most common human cancer and ranked fourth in the list of cancers leading to patient mortality (3).

Platinum-containing antineoplastic drugs are used to treat a wide variety of cancers. Cisplatin, the most commonly prescribed platinum-based drug, is the first line of adjuvant or neoadjuvant treatment of ovarian cancer (4), and has shown promise in an animal model of breast cancer (5). Triple-negative breast cancer cell lines, and ovarian and breast tumors lacking BRCA1 are sensitive to cisplatin (6), and a recent clinical trial is currently assessing the effectiveness of the therapeutic use of cisplatin in breast cancer patients (NCT03012477). The broad efficacy of cisplatin is also extended to colon cancer models (7).

Despite its effectiveness in cancer chemotherapy, the development of resistance to cisplatin has been well reported and is associated with cancer recurrence (4). This resistance is mediated, at least in part, by sequestosome 1 (SQSTM1/p62), which upregulates the Keap1/Nrf-2-antioxidant response element (ARE) signaling cascade and promotes cell survival (8). Improved knowledge of such mechanisms has facilitated further research into combination therapies designed to prevent the development of resistance to cisplatin.

Staurosporine is another broad-spectrum antitumor agent that has shown effectiveness in in vitro models of breast (9), ovarian (6) and colon cancer (10). Although the mode of action of staurosporine is poorly understood, and may involve multiple mechanisms (11), the generation of reactive oxygen species (ROS) has been suggested as a mediator of staurosporine-induced apoptosis (12). We therefore postulated that staurosporine, by its presumed multiple modes of action, may provide additive anticancer effects when co-administered with other chemotherapeutic agents. Hence, we sought to investigate the efficacy of the combination of staurosporine and cisplatin using cell culture models of breast, ovarian, and colon cancers, and to gain insights into the possible action mechanisms involving SQSTM1/p62.

Key words: cisplatin, breast cancer, colon cancer, ovarian cancer, p62, SQSTM1, staurosporine
Materials and methods

**Materials and methods.** The HCT-116 colon cancer cell line and the MCF-7 breast cancer cell line were obtained from the Medical Technology Center of the Medical Research Institute, University of Alexandria, Egypt. Ovarian cancer cell lines (OVCAR3 and OVCAR4) were purchased from the European Collection of Authenticated Cell Cultures (ECACC; Porton Down, Salisbury, UK). Cisplatin was purchased from Invitrogen/Thermo Fisher Scientific, Inc. (Waltham, MA, USA). Dulbecco's modified Eagle's medium (DMEM) and Roswell Park Memorial Institute (RPMI)-1640 media were purchased from HyClone Laboratories, Inc. (Logan, UT, USA). Trypsin-EDTA, phosphate-buffered saline (PBS), and fetal bovine serum (FBS) were purchased from Gibco BRL; Thermo Fisher Scientific, Inc. The CCK-8 cell proliferation assay reagent was obtained from MOLEQULE-ON. Thermo Fisher Scientific, Inc. The CCK-8 cell proliferation assessment reagent was obtained from MOLEQULE-ON. Protein standards, associated detection reagents, Laemmli sample buffer, precast gels, Clarity Western ECL Substrate kit, and Trans-Blot Turbo PVDF Transfer Pack and the ChemiDoc MP Imaging System were all purchased from Bio-Rad Laboratories (Hercules, CA, USA). Mouse monoclonal antibody to glyceraldehyde-3-phosphate dehydrogenase (GAPDH; cat. no. ab9484) and rabbit monoclonal antibody to SQSTM1/p62 (cat. no. ab109012) were purchased from Abcam (Cambridge, UK). Horseradish peroxidase (HRP)-conjugated goat anti-mouse IgG (H+L; cat. no. 170-6516) and goat anti-rabbit IgG (cat. no. 170-5046) were obtained from Bio-Rad Laboratories.

**Cell culture and maintenance.** HCT-116, MCF-7, OVCAR3 and OVCAR4 cells were grown as adherent monolayers and incubated at 37°C under a humidified atmosphere containing 5% CO₂. HCT-116 and MCF-7 cells were maintained in DMEM (10% FBS), while RPMI-1640 medium (10% FBS) was used to culture OVCAR3 and OVCAR4 cells.

**Cell proliferation.** Cells were trypsinized, counted and seeded in 96-well tissue culture plates at a density of 1x10⁴ cells/well. The seeded cells were incubated under standard culture conditions overnight. The next day, media were removed from the wells and fresh media were added onto the double negative wells and the control cells (designated 100% cell proliferation). Serial dilutions of cisplatin and staurosporine were prepared from stock solutions prepared in dimethyl sulfoxide (DMSO) in DMEM or RPMI-1640 as appropriate. Cells were then treated with cisplatin or staurosporine (1-100 µg/ml) or cisplatin + staurosporine (100 µg/ml each). Control and treated cells were incubated for 24 h with medium (control), cisplatin (100 µg/ml), staurosporine (100 µg/ml), or cisplatin + staurosporine (100 µg/ml each). Control and treated cells were washed with ice-cold PBS, scraped, and incubated in 100 µl of ice-cold lysis buffer containing protease inhibitor cocktail. Lysates were spun for 10 min at the maximum speed (13,400 rpm) in a cooling centrifuge and the protein concentration was estimated in the supernatant using the ABC protein estimation kit. Then, 10 µg of protein was loaded into each well of precast gels, electrophoresed and transferred to polyvinylidene difluoride (PVDF) membranes. Membranes were blocked with 5% skim milk in PBS-Tween (PBST) buffer and probed with an anti-p62 antibody (Abcam). Anti-GAPDH was used for normalization and to ensure equal protein loading. Membranes were washed three times in PBST, incubated with the appropriate secondary antibody, washed again, and the signal was detected using the Bio-Rad ECL detection kit. Antibody dilutions were performed according to the instructions in the datasheet.

**Statistical analysis.** Data analysis was performed using GraphPad Prism version 7 (GraphPad Software, Inc., La Jolla, CA, USA). Multivariate statistical comparisons were performed using one-way analysis of variance (ANOVA). Multiple comparisons were conducted between the control group and all other groups, and Dunnett’s post hoc test was employed whenever the P-value was statistically significant (Dunnett’s post hoc test is recommended when comparing multiple groups to a control group). P≤0.05 was considered statistically significant.

**Results.**

Chemoresistance of breast, colon, and ovarian cancer cell lines was reversed in the presence of staurosporine. Cisplatin alone failed to significantly inhibit cell proliferation in comparison to the corresponding negative control following 72 h of incubation at concentrations up to 100 µg/ml. OVCAR3 was the only cell line that showed a partial response to the...
antiproliferative effect of cisplatin (~20% inhibition, though this was not statistically significant) at the highest tested concentration of the drug (100 µg/ml) (Fig. 1A, top graph). Staurosporine treatment, in contrast, resulted in a significant inhibition of MCF-7 (P<0.001), OVCAR3 and OVCAR4 cell proliferation when compared to the corresponding negative control; this inhibition was more significant at higher drug concentrations (P<0.001) (Fig. 1A, bottom graph). Although HCT-116 cells appeared to be more resistant to staurosporine at low concentrations, they were more susceptible at the highest concentration of the drug (100 µg/ml; P<0.001) (Fig. 1A, bottom graph). Fig. 1B and C shows the effect of the co-treatment of staurosporine (100 µg/ml) with cisplatin. Co-treatment with staurosporine helped to overcome cisplatin chemoresistance in HCT-116 (Fig. 1B, top graph), MCF-7 (Fig. 1B, bottom graph), OVCAR3 (Fig. 1C, top graph) and OVCAR4 cells (Fig. 1C, bottom graph). In most cases, the differences between the proliferation rates of cells co-treated with cisplatin and staurosporine and the corresponding control cells were statistically significant; MCF-7 and HCT-116 cells in particular.
A marked restoration of chemoresistance was observed only in the case of OVCAR3 cells at the highest concentration of cisplatin + staurosporine, where there was no significant difference between the proliferation rate of cells treated with both drugs and the negative control (100% cell proliferation), and the pattern of cisplatin effect alone was restored (Fig. 1C, top graph).

Microscopic analysis confirms cisplatin chemoresistance and staurosporine-induced sensitization to cisplatin. The photomicrographs presented in Fig. 2 show the effects of cisplatin, staurosporine, or a combination of the two on cell morphology and viability. Control treatments (incubation with DMEM or RPMI-1640) appeared to increase cell density after 48 h of incubation, with cells exhibiting normal morphology. Cells
incubated with cisplatin for 24 h (Fig. 2A) or 48 h (Fig. 2B) showed normal morphology with no evidence of apoptosis. Incubation of all cell lines with staurosporine for 24 or 48 h resulted in altered morphology (black arrows) indicative of a marked loss of normal cell structure and reduced cell density, with increasing morphological evidence of cell death. Incubation of cells with both drugs (100 µg/ml of each drug) resulted in the loss of cell morphology and a concomitant reduction in viable cells, suggesting additive effects or that staurosporine co-treatment resulted in the sensitization of cells to cisplatin.

Western blotting reveals the contrasting effects of cisplatin and staurosporine on p62 levels. Fig. 3A (western blots) and B (band densitometry charts) show the level of p62 protein in HCT-116, MCF-7, OVCAR3 and OVCAR4 cells cultured under control conditions or incubated with cisplatin, staurosporine, or a combination of the two for 24 h. Whereas cisplatin exposure resulted in an increase in the level of p62 in all cell types compared to the corresponding control cells, staurosporine treatment caused an apparent decrease in p62 levels. Co-administration of staurosporine with cisplatin abrogated the cisplatin-mediated increase in p62 levels in all cell lines when compared to either the corresponding control cells or those treated with cisplatin alone, although these data were not statistically significant as the results are representative of 2 replicates of independent experiments. Therefore, statistical comparisons were not possible for this part. GAPDH levels remained consistent, indicating equal protein loading.

Discussion

The anticancer drugs staurosporine and cisplatin have been extensively studied to investigate their antitumor potential. The mechanism of action of both drugs is believed to involve production of reactive oxygen species (ROS) (13-16). Although cancers do respond to staurosporine in most cases, resistance develops in models where cisplatin is used. In the present study, we investigated the potential of single or combined administration of both drugs to inhibit cellular proliferation in different human cancer cell line models (ovarian, colon, and breast) in an attempt to understand the paradoxical responses observed despite the possibility that a similar mode of action underlies the therapeutic effect of both drugs.

Obvious resistance was observed in all cell lines tested when treated with increasing doses of cisplatin. Resistance to cisplatin was reported in colon cancer in a recent study (17), which reported upregulation of the PI3K pathway and increased levels of X-linked inhibitor of apoptosis (XIAP) as a mediator of this resistance. Similarly, cisplatin resistance was also recently reported in breast cancer (18), and multiple studies have reported the occurrence of cisplatin resistance in ovarian cancer (19-21). Increasing concentrations of staurosporine, in contrast, reduced the proliferation of all cell types tested. These results were confirmed by microscopy, which revealed a loss of normal cell morphology and confirmed the ability of both drugs in combination to inhibit cell proliferation. These observations are in concordance with the reported efficacy of staurosporine in inhibiting the growth of breast cancer cells (9). The antitumor potential of staurosporine in HT-29 colon cancer cells has also been reported, with high, but not low, concentrations of the drug associated with higher expression of carcinoembryonic antigen (CEA). In contrast, low concentrations were associated with lower expression of CEA in C22.20 cells (a sub-line of HT-29), suggesting that staurosporine could be a potent antitumor agent as well as a sensitizer for biomarkers that may aid in diagnosis (22,23). However, a marked regain of resistance was observed in OVCAR3 cells that were co-treated with cisplatin and staurosporine. This pattern of response should draw attention to the importance of further investigation of the impact of cellular characteristics on application of the current hypothesis of using staurosporine (in our case), or other drugs to sensitize cancer cells to platinum-based chemotherapy when chemoresistance is a clinical concern. For example, deciding on drug dose could be an important factor that may have a major influence on sensitization of cells without possible regain of resistance.

The reported antitumor effects of staurosporine are thought to involve the modulation of cell cycle progression and the induction of anti-survival pathways, as reviewed previously (23). Sequestosome 1 (p62), a protein that participates in a survival pathway involving Keap1 and Nrf2, is thought to contribute to cisplatin resistance by allowing translocation of Nrf2 to the nucleus, thereby upregulating antioxidant gene expression in addition to other reported mechanisms (8,24). In this context, because ROS generation has been proposed as a central mediator of the anticancer effects of cisplatin and the Keap1/Nrf2 system is considered to be one possible inducer of cisplatin resistance in cancer cells (25), staurosporine could contribute to a reduction in cisplatin resistance in cancer cells.

In the present study, cisplatin treatment resulted in elevation of p62 levels compared to control cells, whereas staurosporine treatment resulted in an obvious reduction of p62 levels in all three cell types, thereby potentiating the effects of cisplatin. These results suggest that staurosporine could sensitize cancer cells to cisplatin via a mechanism involving the downregulation of p62. It is possible that co-administration of both drugs may reduce cell proliferation and overcome cisplatin resistance in other cancer models.

It is of note to mention that despite reporting p62 as a potential target by which staurosporine could sensitize different types of human cancer cells to cisplatin, this hypothesis should be further investigated and verified in a more comprehensive research model. For example, the role of p62 as a pivotal mediator of cisplatin chemoresistance should be investigated along with the signaling pathways where it functions; the Keap/Nrf/ROS axis, for instance. The influence of upregulation and downregulation of p62 in these types of human cancer cells could be thoroughly investigated by employing gene expression analysis to spot other biomarkers that could be crucial mediators of chemoresistance either independently or by working side-by-side with p62. In addition, experimental models could be used to investigate the potential correlation between p62 upregulation and downregulation and major cell survival pathways for better understanding of the involvement of p62 in the regulation of cell survival and proliferation where staurosporine and cisplatin are used, or, perhaps, other treatment regimens. In this respect, this avenue of research warrants further investigation.
Acknowledgements

Not applicable.

Funding

No funding was received.

Availability of data and materials

The datasets used during the present study are available from the corresponding author upon reasonable request.

Authors' contributions

KA analyzed the data, carried out western blotting experiments and contributed to manuscript writing. OSEM designed the study, carried out cell proliferation experiments and photomicrography and contributed to the manuscript writing. Both authors read and approved the manuscript and agree to be accountable for all aspects of the research in ensuring that the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The authors state that they have no competing interests.

References